Combined drug and CRISPR/CAS9 screening reveals specific targets for SF3B1- and NOTCH1- mutated CLL cells.

DOSTÁLOVÁ, Lenka, Adriana LADUNGOVÁ, Dominika ŠKRNOVÁ, Narendra Varma GOTTUMUKKALA, Yusuf LODHI and Michal ŠMÍDA. Combined drug and CRISPR/CAS9 screening reveals specific targets for SF3B1- and NOTCH1- mutated CLL cells. In EHA 2022 in HemaSphere 2022; 6(S3): 1012-1013. 2022.

Basic information

• Original name: Combined drug and CRISPR/CAS9 screening reveals specific targets for SF3B1- and NOTCH1- mutated CLL cells.
• Authors: DOSTÁLOVÁ, Lenka, Adriana LADUNGOVÁ, Dominika ŠKRNOVÁ, Narendra Varma GOTTUMUKKALA, Yusuf LODHI and Michal ŠMÍDA.
• Edition: EHA 2022 in HemaSphere 2022; 6(S3): 1012-1013, 2022.

Other information

• Type of outcome: Conference abstract
• Confidentiality degree: is not subject to a state or trade secret
• Organization unit: Central European Institute of Technology

Links

• MUNI/A/1330/2021, interní kód MU: Name: Nové přístupy ve výzkumu, diagnostice a terapii hematologických malignit IX (Acronym: VýDiTeHeMa IX)

Investor: Masaryk University

• MUNI/A/1419/2021, interní kód MU: Name: Specifický výzkum v oblasti „Life Sciences“

Investor: Masaryk University

• MUNI/IGA/1516/2020, interní kód MU: Name: Genome-wide CRISPR/Cas9 screening to identify novel therapeutical targets for NOTCH1 and SF3B1 mutated B-cell chronic lymphocytic leukemia

Investor: Masaryk University